Skip to content

NET ASSET VALUE – 31 October 2024

On the 31 October 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,377 million and NAV per share was SEK 56.06.

Allocation of NAV Share of portfolio company Fair value (MSEK) Part of NAV per share (SEK) Share of NAV
Product Development        
Prokarium 42% 488 6.25 11.1%
Xspray Pharma 18% 351 4.50 8.0%
Empros Pharma 79% 204 2.62 4.7%
KAHR Medical 31% 202 2.59 4.6%
Atrogi 37% 176 2.25 4.0%
Lipum 57% 173 2.22 4.0%
Xintela 56% 143 1.84 3.3%
Microbiotica 11% 139 1.78 3.2%
Mendus 24% 123 1.57 2.8%
Geneos Therapeutics 12% 103 1.31 2.3%
Toleranzia 66% 90 1.15 2.1%
EpiEndo Pharmaceuticals 9% 58 0.74 1.3%
Synerkine Pharma 43% 53 0.68 1.2%
AnaCardio 19% 52 0.66 1.2%
Egetis Therapeutics 2% 31 0.40 0.7%
Buzzard Pharmaceuticals 14% 29 0.37 0.7%
Vitara Biomedical 8% 29 0.37 0.7%
Sixera Pharma 23% 26 0.33 0.6%
Alder Therapeutics 21% 17 0.22 0.4%
Amarna Therapeutics 58% 12 0.15 0.3%
Strike Pharma 16% 9 0.11 0.2%
Total   2,507 32.11 57.3%
Commercial Growth      
NorthX Biologics 92% 189 2.42 4.3%
Symcel 31% 169 2.16 3.9%
Provell Pharmaceuticals 72% 75 0.96 1.7%
Chromafora 31% 73 0.93 1.7%
Nanologica 38% 71 0.91 1.6%
A3P Biomedical 8% 42 0.54 1.0%
Frontier Biosolutions 2% 19 0.25 0.4%
Bohus Biotech 45% 17 0.21 0.4%
Total   654 8.38 14.9%
Limited Partnerships, total   94 1.21 2.2%
         
Assets related to Portfolio companies   316 4.05 7.2%
Other assets and liabilities   805 10.31 18.4%
         
Net asset value   4,377 56.06 100.0%
     
       

* indirect shares in Provell Pharmaceuticals